-
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Maternal hemoglobin at 27-29 weeks' gestation and severity of pre-eclampsia.
Cordina M, Bhatti S, Fernandez M, Syngelaki A, Nicolaides KH, Kametas NA.
J Matern Fetal Neonatal Med 2015;27:1-6. pdf -
Longitudinal changes in maternal corin and mid-regional proatrial natriuretic peptide in women at risk of pre-eclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, Elkhouli M, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:190-8. pdf -
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Nanda S, Poon LC, Muhaisen M, Acosta IC, Nicolaides KH.
Metabolism 2012;61:699-705. -
Maternal serum human placental growth hormone (hPGH) at 11 to 13 weeks of gestation in preeclampsia.
Sifakis S, Akolekar R, Mantas N, Kappou D, Nicolaides KH.
Hypertens Pregnancy 2011;30:74-82. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Maternal plasma plasminogen activator inhibitor-2 at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy.
Akolekar R, Cruz JJ, Penco JM, Zhou Y, Nicolaides KH.
Hypertens Pregnancy 2011;30:194-202. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010;30:216-23. -
Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy.
Khalil A, Akolekar R, Pandya P, Syngelaki A, Nicolaides K.
Obstet Gynecol 2010;116:374-80.